172 related articles for article (PubMed ID: 18319717)
1. The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.
Goto T; Takano M; Hirata J; Tsuda H
Br J Cancer; 2008 Mar; 98(6):1068-75. PubMed ID: 18319717
[TBL] [Abstract][Full Text] [Related]
2. Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells.
Wang J; Yang H; Li W; Xu H; Yang X; Gan L
Biochim Biophys Acta; 2015 Mar; 1852(3):395-405. PubMed ID: 25483711
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional role of FOXO1 in drug resistance through antioxidant defense systems.
Goto T; Takano M
Adv Exp Med Biol; 2009; 665():171-9. PubMed ID: 20429424
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
[TBL] [Abstract][Full Text] [Related]
5. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
6. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway.
Ma L; Sun Y; Li D; Li H; Jin X; Ren D
Aging (Albany NY); 2020 Mar; 12(6):5336-5351. PubMed ID: 32202508
[TBL] [Abstract][Full Text] [Related]
8. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Yang H; Shu Z; Jiang Y; Mao W; Pang L; Redwood A; Jeter-Jones SL; Jennings NB; Ornelas A; Zhou J; Rodriguez-Aguayo C; Bartholomeusz G; Iles LR; Zacharias NM; Millward SW; Lopez-Berestein G; Le XF; Ahmed AA; Piwnica-Worms H; Sood AK; Bast RC; Lu Z
Clin Cancer Res; 2019 Sep; 25(18):5702-5716. PubMed ID: 31391192
[TBL] [Abstract][Full Text] [Related]
9. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of H2O2-induced cell death through FOXO1 modulation by EUK-172 in SK-N-MC cells.
Gheysarzadeh A; Yazdanparast R
Eur J Pharmacol; 2012 Dec; 697(1-3):47-52. PubMed ID: 23041154
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer.
Han GH; Chay DB; Nam S; Cho H; Chung JY; Kim JH
BMC Cancer; 2019 Dec; 19(1):1202. PubMed ID: 31823759
[TBL] [Abstract][Full Text] [Related]
13. Trichostatin A modulates intracellular reactive oxygen species through SOD2 and FOXO1 in human bone marrow-mesenchymal stem cells.
Jeong SG; Cho GW
Cell Biochem Funct; 2015 Jan; 33(1):37-43. PubMed ID: 25515622
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
15. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway.
Jinawath N; Vasoontara C; Yap KL; Thiaville MM; Nakayama K; Wang TL; Shih IM
Oncogene; 2009 May; 28(18):1941-8. PubMed ID: 19305429
[TBL] [Abstract][Full Text] [Related]
16. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
17. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells.
Choi HK; Cho KB; Phuong NT; Han CY; Han HK; Hien TT; Choi HS; Kang KW
Mol Pharm; 2013 Jul; 10(7):2517-27. PubMed ID: 23763570
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P
J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
